Previous close | 1,588.00 |
Open | 1,597.50 |
Bid | 1,620.50 x 0 |
Ask | 1,618.00 x 0 |
Day's range | 1,591.00 - 1,631.50 |
52-week range | 866.00 - 1,709.50 |
Volume | |
Avg. volume | 13,177,755 |
Market cap | 4.534T |
Beta (5Y monthly) | 0.63 |
PE ratio (TTM) | 21.01 |
EPS (TTM) | 77.04 |
Earnings date | 10 May 2024 |
Forward dividend & yield | 24.67 (1.52%) |
Ex-dividend date | 28 Mar 2024 |
1y target est | 1,681.80 |
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and BioLabs Global, Inc. (Founder and CEO: Johannes Fruehauf, "BioLabs") and Mitsui Fudosan (TSE: 8801, President and CEO: Takashi Ueda, "Mitsui Fudosan") today announced that they have agreed on a tri-party memorandum of understanding to enhance the life science ecosystem in Tsukuba and Kashiwa-no-ha, Japan, world-renowned science hubs. With this agreement, the three companies will partner to advance SakuLabTM-Tsukub
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Mitsui Fudosan Co., Ltd. (TSE: 8801, President and CEO: Takashi Ueda, "Mitsui Fudosan") announced today that Astellas will establish a "TME imaging and interactive research for innovation (TME iLab)" open innovation hub in October, 2023 in "MITSUI LINK-Lab KASHIWA-NO-HA 1" (Kashiwa City, Chiba Prefecture, "the Lab") operated by Mitsui Fudosan.